Adding liposome-encapsulated irinotecan to standard chemotherapy failed to improve survival as second-line treatment for advanced biliary cancer, a small randomized study showed. Median ...

Please provide your email address to receive an email when new articles are posted on . The phase 3 randomized study, presented at ASCO Annual Meeting, evaluated the overall response rate of ...

During the past few years, six clinical trials have been published on the treatment of advanced or metastatic gastric and gastroesophageal cancer using the combination capecitabine and irinotecan. [54 ...

RECIST v1.1 and irRECIST outcomes in advanced HCC treated with pembrolizumab (pembro). Background: The combination of gemcitabine-cisplatin (GC) is the current standard of care chemotherapy for ...

Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 ...

The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line ...

Please provide your email address to receive an email when new articles are posted on . Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with ...

The market offers key opportunities through the growth of personalized therapies, adoption of monoclonal antibodies, digital health integration, and innovative solutions like irinotecan liposome ...

PARIS--(BUSINESS WIRE)-- Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the United States Food and Drug Administration (FDA) has granted the company Fast Track designation for ...

Starpharma Holdings Limited (AU:SPL) has released an update. Starpharma Holdings Limited reveals encouraging Phase 2 trial outcomes for DEP® irinotecan, showing significant anti-tumor effects and ...

The optimal therapy for patients with metastatic and treatment-refractory colorectal cancer is controversial. Questions with regard to both the sequence and combinations of different drugs need to be ...